Status:
COMPLETED
Use of a Cannabinoids as a Treatment Strategy for Alzheimer's Disease
Lead Sponsor:
Federal University of Latin American Integration
Conditions:
Alzheimer Disease
Eligibility:
All Genders
60+ years
Phase:
PHASE2
Brief Summary
Brief Summary: The objective of the study is to evaluate the effect of cannabinoids on Alzheimer's Disease. This is a double-blind, randomized, placebo-controlled clinical trial. The study aims to re...
Detailed Description
Alzheimer's disease (AD) is closely linked to the accumulation of neurotoxins derived from Aβ and tau, leading to cognitive impairment. This project posits that an imbalance in the endocannabinoid sys...
Eligibility Criteria
Inclusion
- Be over 60 years old;
- Have been diagnosed with AD at least 1 year ago;
- Present mild to moderate symptoms of AD.
Exclusion
- Have a diagnosis of other dementias or factors correlated;
- Present psychosis or first-degree relatives with a history from psychosis, schizophrenia, epilepsy;
- Individuals with a history of psychoactive substance abuse will be included in the study;
- Present severe symptoms of AD.
Key Trial Info
Start Date :
August 13 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 27 2025
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT06570928
Start Date
August 13 2024
End Date
March 27 2025
Last Update
May 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federal University of Latin American Integration
Foz do Iguaçu, Paraná, Brazil, 85870-650